Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 5,425 GBp
Change Today +115.00 / 2.17%
Volume 1.3M
SHP On Other Exchanges
Symbol
Exchange
SHP is not on other exchanges.
As of 12:35 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

5 Riverwalk

Citywest Business Campus

Dublin, 24

Ireland

Phone: 353 1 429 7700

Fax:

Shire plc, together with its subsidiaries, operates as a biopharmaceutical company. The company engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of specialist medicines to meet significant unmet patient needs. Strategy The key elements of the company’s strategy include optimizing in-line assets through commercial excellence; advancing late-stage pipeline and launch new products; accelerating growth through the acquisition of core/adjacent assets; expanding the company’s rare disease expertise and offerings; reinvesting in Research and development; extending the company’s portfolio to new indications and therapeutic areas; collaborating globally to advance the company’s scientific and commercial priorities; operating a lean and agile organization; concentrating operations in Lexington, Massachusetts, the United States and Zug, Switzerland; and executing to a high standard by meeting milestones and delivering on the company’s commitments. Marketed Products Treatments for Neuroscience Attention Deficit Hyperactivity Disorder (ADHD) is a chronic neurobehavioral disorder that manifests as a persistent pattern of inattention and/or hyperactivity-impulsivity that is frequent and severe than is typically observed in individuals at a comparable level of development. Standard treatments include educational approaches, psychological therapies that may include behavior modification, and/or medication. VYVANSE/VENVANSE/ELVANSE/TYVENSE VYVANSE is the pro-drug stimulant for the treatment of ADHD, where the amino acid l-lysine is linked to d-amphetamine. VYVANSE is therapeutically inactive until metabolized in the body. The US Food and Drug Administration (FDA) approved VYVANSE as a once-daily treatment for children aged 6 to 12 with ADHD in 2007, for adults in 2008 and for adolescents aged 13 to 17 in 2010. In addition VYVANSE is approved by the FDA for maintenance treatment, having been approved both as a maintenance treatment in adults with ADHD in 2012, and as a maintenance treatment in pediatrics and adolescents aged 6 to 17 in 2013. VYVANSE is available in the United States in seven dosage strengths, including 10mg, 20mg, 30mg, 40mg, 50mg, 60mg and 70mg. VYVANSE was approved by Health Canada for the treatment of ADHD in pediatric patients aged 6 to 12 in 2009, for adolescents and adults in 2010, and was launched in Canada in 2010 for pediatric patients and 2011 for adolescents and adults. VENVANSE was granted marketing authorization by ANVISA, the Brazilian health authority, for the treatment of ADHD in children aged 6-12, and launched in 2011 and launched for adolescents and adults in 2013. ELVANSE/TYVENSE received a positive outcome from the European Decentralised Procedure in 2012. ELVANSE is indicated as part of a treatment program for ADHD in children 6 years of age and over when response to previous methylphenidate treatment is considered clinically inadequate. The product has received Marketing Authorization approvals and launched in eight countries (the United Kingdom, Germany, Sweden, Spain, Norway, Finland, Denmark, and Ireland). ELVANSE ADULT/ELVANSE VUXEN/ADUVANZ received a positive outcome from the European Decentralised Procedure in January 2015. ELVANSE ADULT is indicated as part of a treatment programme for ADHD in adults taking into consideration the profile of the patient, including a thorough assessment of the severity and chronicity of the patient’s symptoms, the potential for abuse, misuse or diversion and clinical response to any previous pharmacotherapies for the treatment of ADHD. The product has received Marketing Authorization approval in the United Kingdom and Marketing Authorization for Sweden and Denmark is expected in the first quarter of 2015. VYVANSE was also approved in January 2015, for treatment of moderate to severe binge eating disorder (BED). BED is defined as recurring episodes (approximately once weekly), for at least 3 months, of consuming a large amount of food in a short time, compared with others. ADDERALL XR ADDERALL XR is an extended release treatment for ADHD, which uses MICROTROL drug deliver

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SHP:LN 5,425.00 GBp +115.00

SHP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CSL Ltd A$91.85 AUD +0.15
Eisai Co Ltd ¥8,803 JPY -115.00
Hospira Inc $87.88 USD +0.03
Mylan NV $61.63 USD -0.25
UCB SA €68.49 EUR +0.87
View Industry Companies
 

Industry Analysis

SHP

Industry Average

Valuation SHP Industry Range
Price/Earnings 14.2x
Price/Sales 7.7x
Price/Book 5.3x
Price/Cash Flow 13.7x
TEV/Sales 7.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC, please visit www.shire.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.